EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004–2021)

Yanyan Hu, Jiawei Chen, Ling Huang, Congcong Liu, Hongwei Zhou, Rong Zhang

Journal of Medical Microbiology · 08.02.2023 · 72 (2)

DOI: 10.1099/jmm.0.001656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, erschienen am 08.02.2023. Verfasst von Yanyan Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, 310009, P…. Hauptthemen laut MEDLINE: Ceftazidime, Pseudomonas Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa worldwide is a significant global public health concern. Ceftazidime/avibactam (CZA) has been considered a novel promising β-lactam/β-lactamase inhibitor combination antibiotic against difficult-to-treat P. aeruginosa isolates. Big data studies on CZA susceptibility against P. aeruginosa have been limited. Gap statement . Production of metallo-β-lactamases was the most prevalent resistance mechanism for P. aeruginosa against CZA.

Aim

To assess the in vitro activity of CZA against P. aeruginosa strains and the relevant resistance mechanisms. Methodology . One thousand three hundred and sixty-three P. aeruginosa isolates were collected from 2004 to 2021. Antimicrobial susceptibility testing was carried out for commonly used antipseudomonal drugs via the broth microdilution method. Polymerase chain reaction (PCR) or whole-genome sequencing were performed to analyse the most common carbapenemase genes. Molecular epidemiology was analysed by uploading the sequencing data to the Center for Genomic Epidemiology website.

Results

Antimicrobial susceptibility testing showed that CZA and lipopeptides are the most active antibiotics against P. aeruginosa isolates. PCR and genome sequencing revealed that the most prevalent resistance mechanism for P. aeruginosa against CZA was the production of metallo-β-lactamases. None of the bla PDC mutations were found to be associated with avibactam resistance.

Conclusion

Our findings revealed that CZA and lipopeptides are the most active antibiotics against P. aeruginosa isolates. The most prevalent resistance mechanism for P. aeruginosa against CZA was the production of metallo-β-lactamases, and none of the bla PDC mutations were found to be associated with avibactam resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimePseudomonas InfectionsHumansPseudomonas aeruginosaMolecular EpidemiologyAnti-Bacterial Agentsbeta-Lactamase InhibitorsDrug Combinationsbeta-LactamasesMicrobial Sensitivity TestsAzabicyclo Compounds

Stichwörter der Autor:innen

Pseudomonas aeruginosaantimicrobial susceptibilitycarbapenemaseceftazidime/avibactam

Substanzen

CeftazidimeAnti-Bacterial Agentsbeta-Lactamase InhibitorsDrug Combinationsbeta-LactamasesavibactamAzabicyclo Compounds

Autor:innen und Institutionen

  • Clinical Microbiology Laboratory, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, 310009, PR China.
  • Department of Clinical Laboratory Medicine, The Women's and Children's Hospital of Linping District, Hangzhou 311100, PR China.

Förderung

  • the Natural Science Foundation of Zhejiang Province

Zitieren

APA

Hu, Y., Chen, J., Huang, L., Liu, C., Zhou, H., & Zhang, R. (2023). Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004–2021). Journal of Medical Microbiology, 72(2). https://doi.org/10.1099/jmm.0.001656

Vancouver

Hu Y, Chen J, Huang L, Liu C, Zhou H, Zhang R. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004–2021). Journal of Medical Microbiology. 2023;72(2). doi:10.1099/jmm.0.001656

BibTeX
@article{Hu2023,
  author = {Hu, Yanyan and Chen, Jiawei and Huang, Ling and Liu, Congcong and Zhou, Hongwei and Zhang, Rong},
  title = {Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China (2004–2021)},
  journal = {Journal of Medical Microbiology},
  year = {2023},
  volume = {72},
  number = {2},
  doi = {10.1099/jmm.0.001656}
}
Kostenlos starten →